Tumor-Associated Macrophages and the Tumor Immune Microenvironment of Primary and Recurrent Epithelial Ovarian Cancer (EOC).

Related Articles

Tumor-Associated Macrophages and the Tumor Immune Microenvironment of Primary and Recurrent Epithelial Ovarian Cancer (EOC).

Hum Pathol. 2017 Dec 26;:

Authors: Ojalvo LS, Thompson ED, Wang TL, Meeker AK, Shih IM, Fader AN, Cimino-Mathews AM, Emens LA

Abstract
Tumor infiltrating lymphocytes (TILs) are associated with better prognosis in newly diagnosed epithelial ovarian cancer (EOC), but clinical trials of immunotherapies in patients with heavily-treated disease reveal limited activity. Understanding the tumor microenvironment (TME) of primary and recurrent EOC should guide future trials. Here, we evaluated the TME of paired primary and recurrent tumors (n=17), and non-paired primary (n=20) and recurrent (n=15) tumors, for CD8+ T cells, FOXP3+ regulatory T cells (Tregs), CD68+ tumor-associated macrophages (TAMs), programmed cell death protein 1 (PD-1) and programmed cell death ligand 1 (PD-L1). CD8+ T cells were similar in primary and recurrent tumors, but Tregs were higher in recurrent tumors (p=0.0210). Higher TAM density (≥5%) associated with higher Tregs (p=0.001) and CD8+ T cells (p<0.001) in recurrent tumors, but only with higher Tregs in primary tumors (p=0.02). TAM-dense recurrent tumors expressed PD-L1 on tumor and immune cells, whereas TAM-dense primary tumors expressed PD-L1 predominantly on immune cells. In survival analyses, higher Tregs in primary tumors correlated with decreased time to first recurrence (17.0 vs 28.5 months, p=0.022). Conversely, higher Tregs in recurrent tumors correlated with longer overall survival (OS) from recurrence (median not met vs 20.0 months, p=0.022). TAM density did not affect patient survival. However, patients with increased TAMs at recurrence (n=5) had longer OS from recurrence compared to patients without increased TAMs (n=12) (56.0 vs 20.0 months); with the small sample size, this did not reach statistical significance (p=0.074). Further characterization of the evolution of the TME is warranted.

PMID: 29288043 [PubMed - as supplied by publisher]

http://ift.tt/2CpEyQo